Deflux safety information

Deflux safety established over two decades of use

Since 2001, Deflux has been used to treat vesicoureteral reflux (VUR) grades II-IV in children in the United States.

Deflux is the only injectable agent for VUR approved in the United States, Australia, Europe and New Zealand.

Incidence of adverse events occurring >1% of patients1
Adverse Event Category Pivotal study
N=39
Supportive Studies
N=170
Post-Approval Study
N=165
UTI 6 (15.4%) 13 (7.6%) 3 (1.8%)
Ureteral Dilatation 1 (2.6%) 6 (3.5%) 0 (0%)
Nausea, Vomiting, or Abdominal Pain 0 (0%) 2 (1.2%) 0 (0%)

UTI = urinary tract infection

The following adverse events have been reported with Deflux (occurring 1%): ureteral obstruction (some cases requiring temporary placement of a ureteric stent), dysuria, hematuria, urgency, frequency, hydronephrosis, pyelonephritis, urinary tract infection, foreign body reaction, calcification and pyrexia.

Latex-free statement

The components used for the manufacturing of Deflux injectable gel are free from Latex.

Please see the product insert for full safety information.

References:

  1. Deflux prescribing information. Santa Barbara, CA: Palette Life Sciences, Inc.; 2019.
X